Skip to main content
HCPCS Q9999 · Level II · Part B drug

Q9999: ustekinumab-aauz (Otulfi), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q9999

Billing unit
1 MG
Inj ustekinumab-aauz 1 mg
ASP payment limit
$13.246
October 2026; +0.7% vs July 2026
Practitioner MUE
520
MAI 3
OPPS status
SI G
APC 0895
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q9999 is the Level II code for Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $13.246 per billing unit, up 0.7% from July 2026. The practitioner MUE allows up to 520 units per date of service (MAI 3), so a full 520-unit day is $6,887.92 at the current limit. Under OPPS it carries status indicator G in APC 0895. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names ustekinumab: Q9998 (biosimilar ustekinumab-aekn (Selarsdi) from Nupathe Inc); Q9997 (ustekinumab-ttwe (Pyzchiva); intravenous route); Q5138 (biosimilar ustekinumab-auub (Wezlana) from Optum Health Solutions Ireland Limited; intravenous route); Q5100 (biosimilar ustekinumab-kfce (Yesintek) from Biocon Biologics Inc); Q5099 (biosimilar ustekinumab-stba (Steqeyma)); Q5098 (biosimilar ustekinumab-srlf (Imuldosa) from Accord BioPharma, Inc). The ASP crosswalk maps 6 NDCs to it, sold as Otulfi, Ustekinumab-AAUZ by FreseniUS Kabi USA, LLC. No current Billing and Coding Article lists Q9999, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q9999 at $13.246 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $13.154 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q9999
QuarterPayment limitPerCoinsurance
October 2026$13.2461 MG20%
July 2026$13.1541 MG—
CMS note: "lesser of" methodology applied

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 6 NDCs from 1 labeler to Q9999. Report the NDC in the claim's drug segment and bill the number of Q9999 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to Q9999
NDCDrug nameLabelerPackage sizeBilling units / package
65219-0822-05OtulfiFreseniUS Kabi USA, LLC0.5 × 145
65219-0824-01OtulfiFreseniUS Kabi USA, LLC0.5 × 145
65219-0826-26OtulfiFreseniUS Kabi USA, LLC1 × 190
65219-0828-05OtulfiFreseniUS Kabi USA, LLC26 × 1130
65219-0862-01Ustekinumab-AAUZFreseniUS Kabi USA, LLC0.5 × 145
65219-0866-26Ustekinumab-AAUZFreseniUS Kabi USA, LLC1 × 190

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for Q9999. For practitioners the limit is 520 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q9999 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services5203 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital5203 Date of Service Edit: ClinicalPrescribing Information
DME supplier5203 Date of Service Edit: ClinicalPrescribing Information

MUE for Q9999 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q9999 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q9999 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q9999 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q9999 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q9999 carries status indicator G and is assigned to APC 0895, with a published national unadjusted payment of $13.246. Status G marks pass-through drug payment, which is time-limited.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q9999 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $13.25 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q9999 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q9999

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q9999

What does HCPCS code Q9999 describe?

Q9999 is defined by CMS as "Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q9999 a CPT code?

No. Q9999 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as ustekinumab-aauz (Otulfi); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q9999 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q9999 in October 2026?

The ASP-based payment limit is $13.246 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $13.154. Commercial payers use their own fee schedules.

How many units of Q9999 can be billed per day?

The practitioner Medically Unlikely Edit is 520 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q9999?

The October 2026 ASP crosswalk lists 6 NDCs from 1 labeler: Otulfi (FreseniUS Kabi USA, LLC); Ustekinumab-AAUZ (FreseniUS Kabi USA, LLC). For example NDC 65219-0822-05 (package size 0.5) equals 45 billing units of Q9999.

Does Q9999 have NCCI bundling edits?

No active practitioner PTP pairs list Q9999 as a column-1 or column-2 code in the v323r0 release.

Q9999 vs Q9998: what is the difference?

Both are HCPCS Level II codes whose descriptor names ustekinumab. What sets Q9998 apart: biosimilar ustekinumab-aekn (Selarsdi) from Nupathe Inc. Q9999 is billed per 1 mg, limit $13.246, MUE 520; Q9998 is billed per 1 mg, limit $10.48, MUE 520. Report the code whose descriptor matches the product and setting in the record.

Q9999 vs Q9997: what is the difference?

Both are HCPCS Level II codes whose descriptor names ustekinumab. What sets Q9997 apart: ustekinumab-ttwe (Pyzchiva); intravenous route. Q9999 is billed per 1 mg, limit $13.246, MUE 520; Q9997 is billed per 1 mg, limit $8.591, MUE 520. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.